U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
187471187471Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected SubjectsCompletedHas ResultsHIV InfectionsDrug: Maraviroc (UK-427,857)|Drug: optimized background therapy|Drug: Maraviroc (UK-427,857)|Drug: optimized background therapy|Drug: optimized background therapyhttps://ClinicalTrials.gov/show/NCT00098722
187472187472Fetal Pulse Oximetry Trial (FOX)TerminatedNo Results AvailablePregnancyDevice: Fetal pulse oximeterhttps://ClinicalTrials.gov/show/NCT00098709
187473187473Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic SyndromesCompletedNo Results AvailableMyelodysplastic Syndromes|Myelodysplastic/Myeloproliferative NeoplasmsDrug: amifostine trihydratehttps://ClinicalTrials.gov/show/NCT00098683
187474187474Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic LeukemiaCompletedHas ResultsB-cell Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic LeukemiaBiological: alemtuzumab|Biological: rituximab|Drug: fludarabine phosphatehttps://ClinicalTrials.gov/show/NCT00098670
187475187475Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNo Results AvailableMetastatic Squamous Neck Cancer With Occult Primary|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of theDrug: lapatinib ditosylate|Other: laboratory biomarker analysishttps://ClinicalTrials.gov/show/NCT00098631
187476187476Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney CancerTerminatedNo Results AvailableClear Cell Renal Cell Carcinoma|Papillary Renal Cell Carcinoma|Recurrent Renal Cell Cancer|Stage III Renal Cell Cancer|Stage IV Renal Cell CancerDrug: sorafenib tosylate|Biological: recombinant interferon alfa|Other: laboratory biomarker analysishttps://ClinicalTrials.gov/show/NCT00098618
187477187477Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain MetastasesCompletedNo Results AvailableCentral Nervous System Metastases|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Tumors Metastatic to BrainDrug: lapatinib ditosylate|Other: laboratory biomarker analysis|Procedure: quality-of-life assessment|Other: questionnaire administrationhttps://ClinicalTrials.gov/show/NCT00098605
187478187478Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By SurgeryCompletedNo Results AvailableGastrointestinal Stromal Tumor|Recurrent Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue SarcomaDrug: alvocidib|Drug: doxorubicin hydrochloridehttps://ClinicalTrials.gov/show/NCT00098579
187479187479Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNo Results AvailableLymphoma|Quality of Lifehttps://ClinicalTrials.gov/show/NCT00098566
187480187480Everolimus in Treating Patients With Stage IV MelanomaCompletedNo Results AvailableMelanoma (Skin)Drug: everolimushttps://ClinicalTrials.gov/show/NCT00098553
187481187481Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNo Results AvailableRecurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung CancerDrug: sorafenib tosylate|Other: laboratory biomarker analysishttps://ClinicalTrials.gov/show/NCT00098540
187482187482FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction CancerTerminatedNo Results AvailableAdenocarcinoma of the Esophagus|Adenocarcinoma of the Stomach|Recurrent Esophageal Cancer|Recurrent Gastric CancerDrug: romidepsin|Other: laboratory biomarker analysishttps://ClinicalTrials.gov/show/NCT00098527
187483187483Talotrexin in Treating Patients With Advanced or Recurrent Solid TumorsActive, not recruitingNo Results AvailableUnspecified Adult Solid Tumor, Protocol SpecificDrug: talotrexin ammoniumhttps://ClinicalTrials.gov/show/NCT00098514
187484187484CCI-779 and EKB-569 in Treating Patients With Advanced Solid TumorsCompletedNo Results AvailableUnspecified Adult Solid Tumor, Protocol SpecificDrug: pelitinib|Drug: temsirolimushttps://ClinicalTrials.gov/show/NCT00098501
18748518748517-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaTerminatedNo Results AvailableB-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic LeukemiaDrug: tanespimycin|Biological: rituximabhttps://ClinicalTrials.gov/show/NCT00098488
187486187486Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple MyelomaActive, not recruitingHas ResultsDS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell MyelomaDrug: Dexamethasone|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Drug: Thalidomidehttps://ClinicalTrials.gov/show/NCT00098475
187487187487Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung CancerWithdrawnNo Results AvailableLung CancerDrug: gefitinib|Drug: sirolimushttps://ClinicalTrials.gov/show/NCT00098462
187488187488Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory LeukemiasCompletedNo Results AvailableLeukemiaDrug: laromustine|Drug: temozolomidehttps://ClinicalTrials.gov/show/NCT00098436
187489187489Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic SyndromesCompletedNo Results AvailableAccelerated Phase Chronic Myelogenous Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|ADrug: tanespimycin|Drug: cytarabinehttps://ClinicalTrials.gov/show/NCT00098423
187490187490FR901228 in Treating Patients With Metastatic Breast CancerCompletedNo Results AvailableMale Breast Cancer|Recurrent Breast Cancer|Stage IV Breast CancerDrug: romidepsin|Other: laboratory biomarker analysishttps://ClinicalTrials.gov/show/NCT00098397
187491187491Rifaximin Versus Placebo in the Prevention of Travelers' DiarrheaCompletedNo Results AvailableDiarrheaDrug: rifaximinhttps://ClinicalTrials.gov/show/NCT00098384
187492187492Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaTerminatedNo Results AvailableB-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic LeukemiaDrug: alvocidibhttps://ClinicalTrials.gov/show/NCT00098371
187493187493Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne VulgarisActive, not recruitingNo Results AvailableAcne VulgarisDrug: Zileutonhttps://ClinicalTrials.gov/show/NCT00098358
187494187494Efficacy and Tolerability of ZD6474 in Patients With Thyroid CancerActive, not recruitingHas ResultsThyroid CancerDrug: ZD6474 (vandetanib)https://ClinicalTrials.gov/show/NCT00098345
187495187495Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell LymphomaCompletedNo Results AvailableLymphomaDrug: forodesine hydrochloridehttps://ClinicalTrials.gov/show/NCT00098332
187496187496Oral Cleft Prevention Trial in BrazilCompletedNo Results AvailableCleft Lip|Cleft PalateDrug: Folic acid (0.4mg vs. 4.0mg)https://ClinicalTrials.gov/show/NCT00098319
187497187497Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected SubjectsCompletedHas ResultsHIV InfectionsDrug: Maraviroc (UK-427,857)|Drug: Optimized Background Therapy|Drug: Optimized Background Therapy|Drug: Placebo|Drug: Optimized Background Therapyhttps://ClinicalTrials.gov/show/NCT00098306
187498187498Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/LamivudineCompletedHas ResultsHIV-1Drug: Maraviroc + Zidovudine/Lamivudine|Drug: Efavirenz + Zidovudine/Lamivudine|Drug: Maraviroc (UK-427,857) + Zidovudine/Lamivudinehttps://ClinicalTrials.gov/show/NCT00098293
187499187499Eculizumab to Treat Paroxysmal Nocturnal HemoglobinuriaCompletedNo Results AvailableHemoglobinuria, ParoxysmalDrug: Eculizumabhttps://ClinicalTrials.gov/show/NCT00098280
187500187500Collection of Dental Plaque and Saliva for Studies of Bacterial Colonization of TeethCompletedNo Results AvailableHealthyhttps://ClinicalTrials.gov/show/NCT00098267

* Görseller ve İçerik tekif hakkına sahip olabilir